Bayer has announced plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio.  

The modular campus is designed to combine drug-substance and drug-product manufacturing, use digital and automation technologies, and support Bayer’s portfolio initially in oncology, cardiovascular, and renal care. The first module, dedicated to drug-substance manufacturing, is expected to become operational in 2031. A second module for drug product-manufacturing is planned to follow in 2034.  

The new site will complement Bayer’s US pharmaceuticals headquarters in Whippany, New Jersey and its other US sites in the following locations: Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.  

Bayer says the new site builds on more than $7 billion in US pharma R&D and manufacturing spend over the past five years. Bayer says the new site is expected to create approximately 600 jobs and roughly 1,500 construction jobs during the facility’s construction.  

Source: Bayer